Please login to the form below

Not currently logged in
Email:
Password:

Vizamyl

This page shows the latest Vizamyl news and features for those working in and with pharma, biotech and healthcare.

EMA unveils draft guidelines for Alzheimer’s disease research

EMA unveils draft guidelines for Alzheimer’s disease research

Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment

Latest news

  • Biosimilar Lantus leads CHMP opinions Biosimilar Lantus leads CHMP opinions

    event. In addition GE Healthcare received a positive opinion for Vizamyl (flutemetamol) as a diagnostic for Alzheimer's disease. ... Vizamyl is a biomarker that can detect amyloid-beta neuritic plaques, where are formations in the brain associated with

  • CHMP backs Piramal's Alzheimer's imaging agent CHMP backs Piramal's Alzheimer's imaging agent

    18F) and GE Healthcare's Vizamyl (flutemetamol F18) on the market.

  • FDA approves Alzheimer's diagnostic drug FDA approves Alzheimer's diagnostic drug

    FDA approves Alzheimer's diagnostic drug. GE Healthcare's Vizamyl to compete with Lilly's Amyvid. ... A PET scan can then detect the presence of Vizamyl, allowing physicians to evaluate for the presence of beta amyloid.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics